Skip to the page

Data / Drug companies / Strides Pharma Science Limited

Strides Pharma Science Limited: 184 products in the FDA NDC directory, labeler code 64380

Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).

Strides Pharma Science Limited (labeler code 64380) lists 184 products in the FDA National Drug Code Directory, covering 67 finished drugs by generic name. By type: 183 prescription drugs, 1 bulk ingredients. Its main marketing category is generic drugs (ANDA). The newest product started marketing on September 1, 2026.

The request: Watch Strides Pharma Science Limited (FDA labeler code 64380): each new product listing and each discontinued product. $10 of work on sign-up, no card.

SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.

Labeler code
64380
Products in commercial distribution
184
Packages
330
Finished drugs by generic name
67
Prescription products
183
Over the counter products
0
Controlled substance products
Schedule II 9, Schedule III 4, Schedule IV 3
Flagged as original packager
179 of 179 products that carry the flag
Started marketing in the last 12 months
12
Earliest marketing start
September 23, 1997
openFDA record search
api.fda.gov

Products by marketing category

Share of the company's products in commercial distribution.

Marketing categoryProductsShare
Generic drugs (ANDA)18097.8%
Authorized generics (NDA)21.1%
Bulk ingredients10.5%
Other unapproved drugs10.5%

Products by type

TypeProductsShare
Prescription drugs18399.5%
Bulk ingredients10.5%

Drugs it lists

Finished drugs by generic name, with how many companies list each.

Dosage forms

Dosage formProductsShare
Tablet7741.8%
Capsule4021.7%
Tablet, film coated2614.1%
Capsule, liquid filled73.8%
Powder, for solution73.8%
Tablet, orally disintegrating42.2%
Tablet, extended release42.2%
Powder, for suspension42.2%
Suspension31.6%
Gel21.1%
Tablet, coated21.1%
For suspension21.1%

Pharmacologic classes

FDA established pharmacologic classes of its products.

Newest products

By marketing start date.

ProductProduct NDCDosage formMarketing categoryMarketing start
Mycophenolate mofetil64380-899Powder, for suspensionGeneric drugs (ANDA)September 1, 2026
Tramadol hydrochloride64380-778TabletGeneric drugs (ANDA)September 1, 2026
Tramadol hydrochloride64380-791TabletGeneric drugs (ANDA)July 27, 2026
Omega-3-acid ethyl esters64380-761CapsuleGeneric drugs (ANDA)May 29, 2026
Benzonatate64380-713CapsuleGeneric drugs (ANDA)May 29, 2026
Benzonatate64380-712CapsuleGeneric drugs (ANDA)May 29, 2026
Doxycycline hyclate64380-226TabletGeneric drugs (ANDA)May 14, 2026
Doxycycline hyclate64380-225TabletGeneric drugs (ANDA)May 14, 2026
Oxybutynin Chloride64380-190TabletGeneric drugs (ANDA)April 10, 2026
Sumatriptan64380-740Injection, solutionGeneric drugs (ANDA)March 16, 2026
Vancomycin hydrochloride64380-730CapsuleGeneric drugs (ANDA)January 1, 2026
Vancomycin hydrochloride64380-729CapsuleGeneric drugs (ANDA)January 1, 2026
Hydrocodone bitartrate and acetaminophen64380-442TabletGeneric drugs (ANDA)September 1, 2025
Hydrocodone bitartrate and acetaminophen64380-441TabletGeneric drugs (ANDA)September 1, 2025
Hydrocodone bitartrate and acetaminophen64380-440TabletGeneric drugs (ANDA)September 1, 2025
Celecoxib64380-824CapsuleGeneric drugs (ANDA)July 1, 2025
Atomoxetine64380-478CapsuleGeneric drugs (ANDA)July 1, 2025
Atomoxetine64380-477CapsuleGeneric drugs (ANDA)July 1, 2025
Atomoxetine64380-475CapsuleGeneric drugs (ANDA)July 1, 2025
Atomoxetine64380-474CapsuleGeneric drugs (ANDA)July 1, 2025
Atomoxetine64380-473CapsuleGeneric drugs (ANDA)July 1, 2025
Atomoxetine64380-472CapsuleGeneric drugs (ANDA)July 1, 2025
Valganciclovir64380-161Tablet, film coatedGeneric drugs (ANDA)June 16, 2025
Gabapentin64380-728TabletGeneric drugs (ANDA)June 14, 2025
Gabapentin64380-727TabletGeneric drugs (ANDA)June 14, 2025

CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.